<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069379</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00066696</org_study_id>
    <secondary_id>K01MH095920</secondary_id>
    <nct_id>NCT02069379</nct_id>
  </id_info>
  <brief_title>Endogenous Opioid Activity and Affective State in Insulin Resistant Women</brief_title>
  <official_title>Endogenous Opioid Activity and Affective State in Insulin Resistant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance, a primary component of the metabolic syndrome, is an escalating
      phenomenon in the United States, and confers an increased risk of depression and mood
      disorder, particularly in women. The relationship between metabolic and mood disorders may be
      mediated by endogenous opioid activity in limbic brain regions. We propose to examine
      affective state and μ- opioid system function in insulin resistant women, and change in
      response to insulin sensitizing treatment, through the following specific aims and
      hypotheses:

      Establish relationship between insulin resistance, affective state, and μ-opioid receptor
      function.

        1. Insulin resistant women will have greater μ-opioid receptor availability at baseline,
           and a larger response to stress challenge than non-insulin resistant women

        2. Insulin resistant women will have greater negative affective state at baseline, and a
           greater emotional response to stress challenge than non-insulin resistant women.

        3. Mediational analyses will reveal that the relationship between insulin resistance and
           negative affect is mediated by μ-opioid receptor function and neural activation in the
           amygdala and nucleus accumbens affect-regulating regions.

      Examine effects of insulin regulation on μ-opioid receptor function and affective state.

        1. Improved insulin sensitivity will be accompanied by decreased μ-opioid receptor
           availability at baseline and a reduced response to stress challenge. Degree of change in
           baseline receptor availability and response to stress challenge after treatment will
           correlate with degree of insulin regulation.

        2. Improved insulin sensitivity will be associated with improved affective state at
           baseline, and with a reduced emotional response to stress challenge. Degree of change in
           affective state and emotional response to stress challenge after treatment will
           correlate with degree of insulin regulation.

        3. Mediational analyses will reveal that the change in affective state after insulin
           regulation is mediated by change in μ-opioid receptor function and neural activation in
           the amygdala and nucleus accumbens.

      The expected results would suggest a role for the endogenous μ-opioid system in mediating the
      relationship between metabolic function and emotional processes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to examine the role of the endogenous mu-opioid system in
      mediating the relationship between metabolic dysfunction and depressive symptoms in
      reproductive aged women.

      PET image data was unable to be analyzed due to PET equipment replacement midway through
      study, leaving PET images collected at beginning of study incompatible with PET images
      collected later in study.

      Due to insufficient enrollment in treatment arms, the 20 or 40 week data was unusable for
      analytic goals, so the study was re-framed for what could usefully be learned about baseline
      characteristics among the study populations and the originally planned outcome measures were
      amended to only to those that related to understanding the baseline population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">March 24, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State</measure>
    <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
    <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mu-opioid Receptor Binding Potential in Right Nucleus Accumbens, Resting State</measure>
    <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
    <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mu-opioid Receptor Binding Potential in Left Amygdala, Resting State</measure>
    <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
    <description>Mu-opioid neurotransmission in limbic regions at baseline and change from baseline after metformin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mu-opioid Receptor Binding Potential in Right Amygdala, Resting State</measure>
    <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
    <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule - Positive Affective State</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare positive affective state between controls and insulin resistant women. Positive and Negative Affect Schedule - positive affective state. Scores can range from 10-50, with higher scores representing more positive affective state (better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule - Negative Affective State</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of overall negative affective state at baseline in controls and insulin resistant women.
Positive and Negative Affect Schedule - negative affective state. Scores can range from 10-50, with higher scores representing more negative affective state (worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mood States - Overall Negative Mood</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of overall negative mood at baseline in controls and insulin resistant women; Profile of Mood States are standardized to a relative score where a higher score is a worse mood state. Standardized cores generally ranged from - 11 to 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Index</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of depression symptoms at baseline in controls and insulin resistant women. The Beck Depression Index runs on a scale from 0 to 63 where low scores mean less depression and high scores mean greater depression. Clinically, scores of 14 or higher are considered mild depression; 20 is moderate and 29 is severe.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Depression</condition>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 weeks treatment with metformin (insulin sensitizing treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator to metformin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules prepared identically to Metformin capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  18-40 years old

          -  metabolically healthy or insulin resistant (insulin sensitivity &gt; 1.89x10-4 (min-1 x
             µU-1 x mL-1; calculated by minimal model assessment of glucose tolerance test)

          -  body mass index (BMI = weight (kg) / height2 (m2)) between 18 kg/m2 and 35 kg/m2.

          -  Women with mild or moderate depressive symptoms not meeting the criteria for Major
             Depressive Disorder will be included.

        Exclusion Criteria:

          -  men

          -  left handed

          -  acute medical illness

          -  uncorrected thyroid disease

          -  diabetes (fasting glucose ≥126 mg/dL)\

          -  neurological disease

          -  major depression

          -  substance abuse

          -  MRI contraindications (claustrophobia, pacemakers, pumps, metallic agents or devices)

          -  severe calorie restriction

          -  intense physical exercise ≥1 hour/day

          -  smoking within 6 months

          -  hormonal, insulin sensitizing, or centrally acting medications within 2 months

          -  pregnancy within 6 months

          -  lactation

          -  cardiac or pulmonary insufficiency

          -  liver or renal insufficiency (&gt;2.5 x normal transaminases levels, plasma creatinine
             ≥1.4 mg/dL)

          -  history of lactic acidosis

          -  BMI ≥35 kg/m2

          -  opioid allergy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Berent-Spillson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Medical School</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <results_first_submitted>August 19, 2018</results_first_submitted>
  <results_first_submitted_qc>October 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2018</results_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Alison Berent-Spillson</investigator_full_name>
    <investigator_title>Research Investigator</investigator_title>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Mu-opioid system</keyword>
  <keyword>Depression</keyword>
  <keyword>Emotion regulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02069379/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Controls</title>
          <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
        </group>
        <group group_id="P2">
          <title>Insulin Resistant Participants (Placebo First)</title>
          <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
        </group>
        <group group_id="P3">
          <title>Insulin Resistant Participants (Metformin First)</title>
          <description>Women classified as insulin resistant and randomized to Metformin treatment arm 1st and Placebo treatment arm 2nd</description>
        </group>
        <group group_id="P4">
          <title>Insulin Resistant (Not Randomized)</title>
          <description>Insulin resistant participants not randomized to treatment arms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline Measurements</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline Measurements Taken</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible based on initial assessments</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Treatment Arm</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Controls are not involved after initial baseline collection</participants>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0">Insulin resistant woman not randomized are not involved after initial baseline collection</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Controls are not involved after initial baseline collection</participants>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0">Insulin resistant woman who were not randomized are not involved after initial baseline collection</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Treatment Arm</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Controls are not involved after initial baseline collection</participants>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0">Insulin resistant women who are not randomized are not involved after initial baseline collection</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All insulin resistant women are grouped together for baseline characteristics, as these measurements were taken prior to treatment arm randomization</population>
      <group_list>
        <group group_id="B1">
          <title>Controls</title>
          <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
        </group>
        <group group_id="B2">
          <title>Insulin Resistant Participants</title>
          <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.29" spread="5.33"/>
                    <measurement group_id="B2" value="84.67" spread="9.99"/>
                    <measurement group_id="B3" value="81.60" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Insulin Levels</title>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.18" spread="1.99"/>
                    <measurement group_id="B2" value="18.61" spread="3.36"/>
                    <measurement group_id="B3" value="12.71" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA Insulin Resistance (IR)</title>
          <units>HOMA IR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.01" spread="0.42"/>
                    <measurement group_id="B2" value="3.94" spread="1.11"/>
                    <measurement group_id="B3" value="2.56" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State</title>
        <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
        <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
        <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>16 weeks treatment with metformin (insulin sensitizing treatment)
Metformin: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator to metformin treatment
Placebo: Placebo capsules prepared identically to Metformin capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State</title>
          <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
          <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mu-opioid Receptor Binding Potential in Right Nucleus Accumbens, Resting State</title>
        <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
        <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
        <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>16 weeks treatment with metformin (insulin sensitizing treatment)
Metformin: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator to metformin treatment
Placebo: Placebo capsules prepared identically to Metformin capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mu-opioid Receptor Binding Potential in Right Nucleus Accumbens, Resting State</title>
          <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
          <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mu-opioid Receptor Binding Potential in Left Amygdala, Resting State</title>
        <description>Mu-opioid neurotransmission in limbic regions at baseline and change from baseline after metformin treatment</description>
        <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
        <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>16 weeks treatment with metformin (insulin sensitizing treatment)
Metformin: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator to metformin treatment
Placebo: Placebo capsules prepared identically to Metformin capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mu-opioid Receptor Binding Potential in Left Amygdala, Resting State</title>
          <description>Mu-opioid neurotransmission in limbic regions at baseline and change from baseline after metformin treatment</description>
          <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mu-opioid Receptor Binding Potential in Right Amygdala, Resting State</title>
        <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
        <time_frame>Baseline, 20 weeks, 40 weeks</time_frame>
        <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>16 weeks treatment with metformin (insulin sensitizing treatment)
Metformin: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator to metformin treatment
Placebo: Placebo capsules prepared identically to Metformin capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mu-opioid Receptor Binding Potential in Right Amygdala, Resting State</title>
          <description>Mu-opioid neurotransmission in limbic brain regions at baseline and change from baseline after metformin treatment</description>
          <population>PET scanners available were replaced for other institutional reasons which resulted in image production so incompatible as to be not comparable. Therefore PET image data files were unable to be analyzed due to inconsistencies with imaging techniques.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule - Positive Affective State</title>
        <description>Compare positive affective state between controls and insulin resistant women. Positive and Negative Affect Schedule - positive affective state. Scores can range from 10-50, with higher scores representing more positive affective state (better outcome)</description>
        <time_frame>Baseline</time_frame>
        <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women are analyzed as a single group. On the Control side, one woman's data for affective state is unavailable.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Resistant Participants</title>
            <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule - Positive Affective State</title>
          <description>Compare positive affective state between controls and insulin resistant women. Positive and Negative Affect Schedule - positive affective state. Scores can range from 10-50, with higher scores representing more positive affective state (better outcome)</description>
          <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women are analyzed as a single group. On the Control side, one woman's data for affective state is unavailable.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.23" spread="8.29"/>
                    <measurement group_id="O2" value="21.83" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule - Negative Affective State</title>
        <description>Measure of overall negative affective state at baseline in controls and insulin resistant women.
Positive and Negative Affect Schedule - negative affective state. Scores can range from 10-50, with higher scores representing more negative affective state (worse outcome)</description>
        <time_frame>Baseline</time_frame>
        <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women analyzed as a single group. One woman's baseline affective score is not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Resistant Participants</title>
            <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule - Negative Affective State</title>
          <description>Measure of overall negative affective state at baseline in controls and insulin resistant women.
Positive and Negative Affect Schedule - negative affective state. Scores can range from 10-50, with higher scores representing more negative affective state (worse outcome)</description>
          <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women analyzed as a single group. One woman's baseline affective score is not available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" spread="1.68"/>
                    <measurement group_id="O2" value="12.83" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Profile of Mood States - Overall Negative Mood</title>
        <description>Measure of overall negative mood at baseline in controls and insulin resistant women; Profile of Mood States are standardized to a relative score where a higher score is a worse mood state. Standardized cores generally ranged from - 11 to 52.</description>
        <time_frame>Baseline</time_frame>
        <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women analyzed as a single group; one woman on the control side's data is not available</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Resistant Participants</title>
            <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Profile of Mood States - Overall Negative Mood</title>
          <description>Measure of overall negative mood at baseline in controls and insulin resistant women; Profile of Mood States are standardized to a relative score where a higher score is a worse mood state. Standardized cores generally ranged from - 11 to 52.</description>
          <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women analyzed as a single group; one woman on the control side's data is not available</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="10.60"/>
                    <measurement group_id="O2" value="14.42" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Index</title>
        <description>Measure of depression symptoms at baseline in controls and insulin resistant women. The Beck Depression Index runs on a scale from 0 to 63 where low scores mean less depression and high scores mean greater depression. Clinically, scores of 14 or higher are considered mild depression; 20 is moderate and 29 is severe.</description>
        <time_frame>Baseline</time_frame>
        <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women analyzed as a single group. The data for one woman in the control group is unavailable. Note: women with BDI scores of greater than 20 were excluded from the study by definition and therefore could not be in either arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Controls</title>
            <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
          </group>
          <group group_id="O2">
            <title>Insulin Resistant Participants</title>
            <description>Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Index</title>
          <description>Measure of depression symptoms at baseline in controls and insulin resistant women. The Beck Depression Index runs on a scale from 0 to 63 where low scores mean less depression and high scores mean greater depression. Clinically, scores of 14 or higher are considered mild depression; 20 is moderate and 29 is severe.</description>
          <population>All women assessed at baseline, prior to treatment arm randomization, so all insulin resistant women analyzed as a single group. The data for one woman in the control group is unavailable. Note: women with BDI scores of greater than 20 were excluded from the study by definition and therefore could not be in either arm.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="4.36"/>
                    <measurement group_id="O2" value="7.00" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for up to 40 weeks of study participation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Controls</title>
          <description>metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (First Assignment &amp; Washout or Second Assignment)</title>
          <description>Placebo comparator to metformin treatment
Placebo: Placebo capsules prepared identically to Metformin capsules</description>
        </group>
        <group group_id="E3">
          <title>Metformin (First Assignment &amp; Washout or Second Assignment)</title>
          <description>16 weeks treatment with metformin (insulin sensitizing treatment)
Metformin: Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.</description>
        </group>
        <group group_id="E4">
          <title>Insulin-resistant Women Not Randomized</title>
          <description>These participants, like controls, did not continue beyond baseline and were not assigned any metformin or placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea?</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Self-reported seizure</sub_title>
                <description>Participant reported undiagnosed seizure during placebo treatment; study participation was halted</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Brain lesion detected</sub_title>
                <description>Brain lesion was detected during study MRI scan. Participant notified and spoke with study radiologist, and referred to diagnostic radiologist care.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated potassium levels</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation of this study is the relatively small sample size of the insulin resistant group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alison Berent-Spillson</name_or_title>
      <organization>University of Michigan</organization>
      <phone>(734) 936-4400</phone>
      <email>berent@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

